WO2025262570 - VENGLUSTAT AS AN INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE IN SUBJECTS HAVING HEPATIC IMPAIRMENT
National phase entry is expected:
Publication Number
WO/2025/262570
Publication Date
26.12.2025
International Application No.
PCT/IB2025/056136
International Filing Date
16.06.2025
Title **
[English]
VENGLUSTAT AS AN INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE IN SUBJECTS HAVING HEPATIC IMPAIRMENT
[French]
VENGLUSTAT UTILISÉ COMME INHIBITEUR DE LA GLUCOSYLCÉRAMIDE SYNTHASE CHEZ DES SUJETS PRÉSENTANT UNE DÉFICIENCE HÉPATIQUE
Applicants **
GENZYME CORPORATION
Inventors
CARTOT COTTON, Sylvaine
SHARMA, Jyoti
Priority Data
63/660,770
17.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2550 | |
| EPO | Filing, Examination, Granting | 14112 | |
| Japan | Filing, Examination, Granting | 2461 | |
| South Korea | Filing, Examination, Granting | 2699 | |
| USA | Filing, Examination, Granting | 9340 |
Total:
31,162
Contact Us
Abstract[English]
Provided herein are methods in which subjects having hepatic impairment are administered venglustat. The methods are directed, in particular, at subjects having mild or moderate hepatic impairment.[French]
L'invention concerne des méthodes selon lesquelles le venglustat est administré à des sujets atteints d'une déficience hépatique. Ces méthodes sont destinées, en particulier, à des sujets atteints d'une déficience hépatique légère ou modérée.